CooperVision Myopia Control Research receives Garland W. Clay Award

The American Academy of Optometry has awarded the 2021 Garland W. Clay Prize to a team of researchers studying the effectiveness of CooperVision MiSight® 1-day contact lenses in slowing the progression of myopia in children (ages 8 to 12 years at the start of treatment). ??[1] The prestigious award is presented annually to the author (s) of the most significant article published in Optometry and Vision Science within the previous five years. The authors of the winning article, “A 3-Year Randomized Clinical Trial of MiSight® Lenses for Myopia Control”, include:

Paul Chamberlain, B.Sc. (Hons.)
Sofia C. Peixoto-De-Matos, MSc
Nicola S. Logan, PhD
Cheryl Ngo, MBBS, MMed
Deborah Jones, BSc, FAAO
and Graeme Young, PhD, FAAO.

The Optometry and Vision Science Editorial Board awards the annual Garland W. Clay Prize based on criteria such as the number of citations in the global scientific literature, the impact of the science of vision, the value to the practice of l optometry and the relevance of the American Academy’s mission. of Optometry. After only two years since its publication, the MiSight® 1 Day Contact Lenses article has been cited over 70 times according to the Clarivate Web of Science and is the most cited article in optometry and vision science. since 2016.

Optometry and Vision Sciences Editor-in-Chief Michael Twa, OD, PhD, FAAO stressed that his publication prioritizes quality, evidence-based publications, noting that: “The results of clinical trials provide strong evidence that it is possible to slow eye growth that causes worsening myopia. Research into controlling myopia is evolving rapidly, and effective treatments may do more than improve vision, they can also help reduce lifelong risks of glaucoma, retinal detachments and other degenerative eye conditions.[2]

CooperVision MiSight® 1 Day Contact Lenses have been shown to control myopia to slow the progression of myopia in children aged 8 to 12 years at the start of treatment. † 1 Evidence gleaned from these three years of research has laid the groundwork for the FDA * approval of CooperVision MiSight® lenses in 2019. The study, a double-blind, randomized clinical trial, demonstrated the effectiveness of MiSight® lenses in reducing the rate of myopia progression in children (aged 8 to 12 at the start of treatment) by 59% on average over a three-year period. † 1

CooperVision’s Director of Research Programs, Paul Chamberlain, BSc (Hons.) Said, “Our team is grateful to the Optometry and Vision Science Editorial Board and the American Academy of Optometry for recognizing our work. It is very satisfying to know that our research on myopia control is helping age-appropriate children and their parents around the world. And it is truly an honor to be associated with the other pioneer newspapers that have already received this distinction. “

Chamberlain and his team received the Garland W. Clay Award at the American Academy of Optometry meeting in Boston on Thursday, November 4. available online via Open Access.

###

[1] Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for the control of myopia. Optom Vis Sci. 2019; 96 (8): 556-567. [2] Flitcroft DI. The complex interactions of retinal, optical and environmental factors in the etiology of myopia. Prog Retin Eye Res. 2012; 31: 622-60.

Copyright © acrofan All rights reserved

Source link

About Marion Alexander

Check Also

Don’t wait for Biden’s antitrust revolution

On July 9, President Joe Biden issued an executive order promoting competition in the US …

Leave a Reply

Your email address will not be published. Required fields are marked *